World Journal of Clinical Oncology

metrics 2024

Illuminating the Path to Oncology Excellence

Introduction

World Journal of Clinical Oncology, published by BAISHIDENG PUBLISHING GROUP INC, stands as a vital resource in the realm of oncology, providing a dedicated platform for the dissemination of cutting-edge research and clinical advancements. With an ISSN of 2218-4333, this journal facilitates a comprehensive exploration of modern oncology challenges and breakthroughs, targeting researchers, healthcare professionals, and students alike. Although it operates under the traditional subscription model, the impactful nature of its content is reflected in its notable ranking of 60 out of 334 in the category of Medicine _ Oncology, placing it in the 82nd percentile among peer publications. Covering significant topics in clinical oncology from 2014 to 2018, the journal has been instrumental in addressing evolving oncology practices and patient care innovations. By publishing high-quality studies, it remains an essential tool for advancing knowledge and fostering collaboration within the global oncology community.

Metrics 2024

SCIMAGO Journal Rank-
Journal Impact Factor2.60
Journal Impact Factor (5 years)2.70
H-Index-
Journal IF Without Self2.60
Eigen Factor0.00
Normal Eigen Factor0.35
Influence0.65
Immediacy Index0.50
Cited Half Life6.70
Citing Half Life5.50
JCI0.41
Total Documents-
WOS Total Citations1852
SCIMAGO Total Citations-
SCIMAGO SELF Citations-
Scopus Journal Rank1.00
Cites / Document (2 Years)-
Cites / Document (3 Years)-
Cites / Document (4 Years)-

Metrics History

Rank 2024

Scopus

Oncology in Medicine
Rank #60/334
Percentile 82.04
Quartile Q1

IF (Web Of Science)

ONCOLOGY
Rank 175/322
Percentile 45.80
Quartile Q3

JCI (Web Of Science)

ONCOLOGY
Rank 237/322
Percentile 26.40
Quartile Q3

Quartile History

Similar Journals

Future Oncology

Bridging laboratory innovation with clinical excellence.
Publisher: FUTURE MEDICINE LTDISSN: 1479-6694Frequency: 40 issues/year

Future Oncology is a premier peer-reviewed journal published by FUTURE MEDICINE LTD, dedicated to advancing research and innovation within the field of oncology. Established in 2005 and set to continue through 2024, this journal serves as an essential resource for researchers, healthcare professionals, and students engaged in cancer studies. With its emphasis on groundbreaking findings and multidisciplinary approaches, Future Oncology holds an esteemed reputation, reflected in its 2023 category quartiles ranking it in Q2 for Cancer Research and Q1 for Medicine (miscellaneous). The journal is indexed in Scopus, showcasing its rigorous content, with rankings in the 63rd percentile for Oncology and the 46th percentile for Cancer Research. Although it does not operate on an open-access model, its commitment to disseminating cutting-edge findings makes it an invaluable asset for those seeking to stay at the forefront of oncology research.Future Oncology strives to bridge the gap between laboratory and clinical research, fostering collaboration and appreciation for the complexities of cancer treatment.

ONCOLOGY

Elevating the standards of oncology research and practice.
Publisher: KARGERISSN: 0030-2414Frequency: 12 issues/year

ONCOLOGY is a prestigious journal published by KARGER, dedicated to advancing the field of cancer research and treatment. Established in 1948, this peer-reviewed journal has established a significant presence in the medical community, reflected by its impressive impact factor and Q2 category rankings in both Cancer Research and Oncology as of 2023. With a focus on groundbreaking research and comprehensive reviews, ONCOLOGY serves as a crucial resource for researchers, clinicians, and students interested in the latest developments in the fight against cancer. Although it currently does not offer open access, the journal's reputation ensures that it reaches a wide audience in academia and clinical practice. Its commitment to excellence is underscored by its consistent rankings in key disciplines, making it a vital publication for anyone involved in cancer research, biology, or associated medical fields. The journal is headquartered in Basel, Switzerland, positioning it at the heart of European medical research.

LUNG CANCER

Empowering Research, Enhancing Lives
Publisher: ELSEVIER IRELAND LTDISSN: 0169-5002Frequency: 12 issues/year

LUNG CANCER, published by Elsevier Ireland Ltd, is a pivotal academic journal dedicated to advancing knowledge in the fields of Cancer Research, Oncology, and Pulmonary and Respiratory Medicine. With an impressive impact factor reflected by its Q1 ranking across three key categories for 2023, this journal occupies a prestigious position within the research community, emphasizing quality and significance in published works. Since its inception in 1985, LUNG CANCER has provided a comprehensive platform for researchers and clinicians to disseminate findings and novel insights, enhancing the understanding and treatment of lung cancer. The journal stands out with Scopus rankings, placing it in the top percentile across multiple relevant fields, including a notable rank of #20 in Pulmonary and Respiratory Medicine. By fostering collaboration among scholars, the journal aims to facilitate innovative research and promote evidence-based practices that could transform patient outcomes. As such, LUNG CANCER is an essential resource for those navigating this complex area of study, from seasoned researchers to aspiring professionals.

Clinical Medicine Insights-Oncology

Illuminating the path to improved patient outcomes.
Publisher: SAGE PUBLICATIONS LTDISSN: Frequency: 1 issue/year

Clinical Medicine Insights-Oncology is a leading journal published by SAGE Publications Ltd, focusing on the interdisciplinary aspects of oncology. With an open access model since 2007, this journal fosters the dissemination of high-quality research and clinical insights that are crucial for advancing knowledge in cancer treatment and management. Based in New Zealand, it aims to bridge gaps in current oncology practices through the publication of innovative studies, case reports, and reviews. With a respectable ranking in Scopus at #264 out of 404 journals in the oncology category and belonging to the Q3 quartile, it positions itself as a valuable resource for oncologists, researchers, and students committed to enhancing patient outcomes. This journal strives to provide a platform for groundbreaking research that can impact clinical practice and inform policy within the field of oncology.

Oncology Reviews

Exploring Innovations in Cancer Treatment and Research
Publisher: FRONTIERS MEDIA SAISSN: 1970-5557Frequency: 2 issues/year

Oncology Reviews, founded in 2007 and published by FRONTIERS MEDIA SA, is a leading open-access journal dedicated to advancing knowledge in the field of oncology and cancer research. With an Impact Factor reflecting its robust engagement in scholarly discourse, this journal maintains a prestigious standing, earning a Q2 ranking in Oncology and a Q3 ranking in Cancer Research as of 2023. Notably, it is indexed in Scopus, where it ranks #118 in Oncology and #98 in Cancer Research, highlighting its global reach and significance. The journal's open-access policy, in effect since 2012, ensures that high-quality research is accessible to all, fostering collaboration and wellness improvements worldwide. This commitment to accessibility and dissemination of pivotal research makes Oncology Reviews an essential resource for researchers, healthcare professionals, and students eager to contribute to and stay abreast of the latest innovations in cancer treatment and research.

Breast Cancer

Exploring the latest in breast cancer science and care.
Publisher: SPRINGER JAPAN KKISSN: 1340-6868Frequency: 6 issues/year

Breast Cancer is a prestigious peer-reviewed journal published by SPRINGER JAPAN KK, specializing in the multifaceted domains of oncology and medical pharmacology. With an impressive impact factor and recognized within the Q1 category in multiple areas, including Medicine (miscellaneous), Radiology, and Nuclear Medicine and Imaging, this journal serves as a fundamental resource for cutting-edge research and clinical advancements in breast cancer treatment and care. Its indexed presence in renowned databases like Scopus further affirms its significance, ranking 56th in Radiology and 60th in Pharmacology. The journal aims to bridge the gap between clinical practice and scientific research by publishing original articles, reviews, and case studies that enhance understanding and improve patient outcomes. With converged content available from 1994 to 2024, the journal is dedicated to fostering innovative research while engaging a global audience of researchers, clinicians, and students passionate about tackling breast cancer challenges.

JOURNAL OF CLINICAL ONCOLOGY

Fostering a community dedicated to advancing cancer knowledge.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0732-183XFrequency: 36 issues/year

Journal of Clinical Oncology is a premier academic journal published by Lippincott Williams & Wilkins, dedicated to the field of oncology and cancer research. Since its inception in 1983, this influential journal has consistently ranked in the Q1 category across multiple disciplines, including cancer research, medicine, and oncology, reflecting its critical role in shaping the future of cancer therapeutics and patient care. With a Scopus ranking of #9 in Medicine - Oncology and #6 in Biochemistry, Genetics and Molecular Biology - Cancer Research, Journal of Clinical Oncology publishes cutting-edge original research, reviews, and clinical updates that are essential for professionals, researchers, and students alike. Although it does not currently offer open access options, it provides invaluable insights and evidence-based findings that are crucial for advancing oncological knowledge and improving patient outcomes globally. The journal’s continued commitment to excellence ensures its place as a vital resource in the oncological community.

BREAST CANCER RESEARCH AND TREATMENT

Exploring New Frontiers in Oncology
Publisher: SPRINGERISSN: 0167-6806Frequency: 18 issues/year

Breast Cancer Research and Treatment, published by Springer, stands as a pivotal journal within the domains of Cancer Research and Oncology, exemplified by its impressive Q2 and Q1 quartile rankings, respectively, in the 2023 category rankings. Since its inception in 1981, this journal has provided a vital platform for disseminating cutting-edge research focused on all aspects of breast cancer, ranging from molecular biology to treatment strategies. With an ISSN of 0167-6806 and E-ISSN of 1573-7217, it captures a broad audience of researchers, clinicians, and students dedicated to improving patient outcomes. The journal emphasizes high-quality, peer-reviewed studies that pave the way for advancements in therapy and direct novel insights into oncological practices. By maintaining a strong ranking in Scopus with percentile placements of 74th in Oncology and 61st in Cancer Research, Brest Cancer Research and Treatment continues to foster innovation and collaboration in the fight against breast cancer.

Colorectal Cancer

Enhancing Visibility for Groundbreaking Research
Publisher: TAYLOR & FRANCIS LTDISSN: 1758-194XFrequency: 4 issues/year

Colorectal Cancer is an esteemed academic journal published by Taylor & Francis Ltd, focusing on all aspects of colorectal cancer research, diagnosis, treatment, and prevention. With an ISSN of 1758-194X and an E-ISSN of 1758-1958, this journal serves as a critical platform for publishing innovative studies, clinical trials, and meta-analyses to advance the understanding of colorectal cancer. Though not yet categorized under open access, it provides valuable insights and is committed to enhancing the visibility of research contributions within the field. The journal aims to foster collaboration and communication among researchers, clinicians, and students dedicated to improving patient outcomes and exploring novel therapeutic strategies. With its rigorous editorial standards, Colorectal Cancer plays a pivotal role in shaping future research and clinical practices, making it indispensable for professionals in oncology, gastroenterology, and related fields.

European Urology Oncology

Empowering professionals with cutting-edge insights in urology and oncology.
Publisher: ELSEVIERISSN: Frequency: 6 issues/year

European Urology Oncology is a premier academic journal dedicated to advancing the field of urological oncology through innovative research and interdisciplinary collaboration. Published by Elsevier and based in the Netherlands, this journal runs on the principles of providing high-quality, peer-reviewed content that meets the evolving needs of professionals in medicine, surgery, and oncology. With an impressive 2023 categorization in the Q1 quartiles across multiple disciplines including Medicine (Miscellaneous), Oncology, and Urology, the journal demonstrates its pivotal role in disseminating essential findings that enhance clinical practices. The E-ISSN of this journal is 2588-9311, ensuring accessibility to groundbreaking articles that influence treatment methodologies and patient outcomes. Researchers and professionals relying on the latest evidence in urology and oncology will find this journal essential for keeping abreast of cutting-edge developments and clinical insights that shape the future of healthcare.